Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes

Sarunporn Kamolvisit, Supphamat Chirnaksorn, Hataikarn Nimitphong, Somnuek Sungkanuparph

Cureus · 2021 · 11 citations · 18 references

DOIFull text

Open access

Concepts

Abstract

Metabolic-associated fatty liver disease (MAFLD) is increasingly common among people living with the human immunodeficiency virus (PLHIV) and can progress to cirrhosis and cirrhotic-related complications. Pioglitazone is known to improve insulin sensitivity that results in decreasing serum fatty acids and resolution of non-alcoholic steatohepatitis. This study was aimed to evaluate the efficacy of pioglitazone for the treatment of MAFLD in PLHIV and prediabetes.

References

18